In this section, we review three common modalities of targeted therapy for NSCLC, namely, EGFR-TKI, KRAS inhibitor therapy, and GPCR inhibitor therapy, and look forward to new research directions for these three treatment modalities. This evidence concerns the gene KRAS and non-small cell lung carcinoma.